prednisone has been researched along with Limb-Girdle Muscular Dystrophies in 6 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this single center, open label pilot study, once-weekly prednisone was safe and well tolerated." | 3.11 | An Open Label Exploratory Clinical Trial Evaluating Safety and Tolerability of Once-Weekly Prednisone in Becker and Limb-Girdle Muscular Dystrophy. ( Ajroud-Driss, S; Casey, P; Joslin, BC; McNally, EM; Zelikovich, AS, 2022) |
| " Herein, we assessed the efficacy of steroid dosing on sarcolemmal repair, muscle function, histopathology, and the regenerative capacity of primary muscle cells." | 1.46 | Intermittent Glucocorticoid Dosing Improves Muscle Repair and Function in Mice with Limb-Girdle Muscular Dystrophy. ( Demonbreun, AR; McNally, EM; Page, PG; Quattrocelli, M; Salamone, IM; Warner, JL, 2017) |
| "Alendronate treatment did not ameliorate muscle degeneration, but demonstrated a limited enhancement on muscle function test." | 1.43 | Glucocorticoid Steroid and Alendronate Treatment Alleviates Dystrophic Phenotype with Enhanced Functional Glycosylation of α-Dystroglycan in Mouse Model of Limb-Girdle Muscular Dystrophy with FKRPP448L Mutation. ( Blaeser, A; Bollinger, LE; Cox, MD; Harper, AD; Lu, P; Lu, QL; Luckie, TM; Madden, KL; Richardson, SM; Shah, SN; Sparks, S; Sun, Y; Wu, B, 2016) |
| "Prednisone therapy was associated with: (i) functional improvement of overall motor disability, in upper limbs of DMD (P < 0." | 1.33 | The effects of glucocorticoid therapy on the inflammatory and dendritic cells in muscular dystrophies. ( Abu-Dief, EE; Hamed, SA; Hussein, MR; Kamel, NF; Kandil, MR; Mostafa, MG, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Zelikovich, AS | 1 |
| Joslin, BC | 1 |
| Casey, P | 1 |
| McNally, EM | 2 |
| Ajroud-Driss, S | 1 |
| Quattrocelli, M | 1 |
| Salamone, IM | 1 |
| Page, PG | 1 |
| Warner, JL | 1 |
| Demonbreun, AR | 1 |
| Dadgar, S | 1 |
| Wang, Z | 1 |
| Johnston, H | 1 |
| Kesari, A | 1 |
| Nagaraju, K | 1 |
| Chen, YW | 1 |
| Hill, DA | 1 |
| Partridge, TA | 1 |
| Giri, M | 1 |
| Freishtat, RJ | 1 |
| Nazarian, J | 1 |
| Xuan, J | 1 |
| Wang, Y | 1 |
| Hoffman, EP | 1 |
| Wu, B | 1 |
| Shah, SN | 1 |
| Lu, P | 1 |
| Richardson, SM | 1 |
| Bollinger, LE | 1 |
| Blaeser, A | 1 |
| Madden, KL | 1 |
| Sun, Y | 1 |
| Luckie, TM | 1 |
| Cox, MD | 1 |
| Sparks, S | 1 |
| Harper, AD | 1 |
| Lu, QL | 1 |
| Godfrey, C | 1 |
| Escolar, D | 1 |
| Brockington, M | 1 |
| Clement, EM | 1 |
| Mein, R | 1 |
| Jimenez-Mallebrera, C | 1 |
| Torelli, S | 1 |
| Feng, L | 1 |
| Brown, SC | 1 |
| Sewry, CA | 1 |
| Rutherford, M | 1 |
| Shapira, Y | 1 |
| Abbs, S | 1 |
| Muntoni, F | 1 |
| Hussein, MR | 1 |
| Hamed, SA | 1 |
| Mostafa, MG | 1 |
| Abu-Dief, EE | 1 |
| Kamel, NF | 1 |
| Kandil, MR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open Label Safety and Efficacy of Once Weekly Steroid in Patients With LGMD and Becker Muscular Dystrophy[NCT04054375] | Phase 2 | 20 participants (Actual) | Interventional | 2019-07-01 | Completed | ||
| A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study With Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)[NCT03439670] | Phase 2 | 121 participants (Actual) | Interventional | 2018-06-29 | Completed | ||
| A Phase II Open-Label, Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD)[NCT05185622] | Phase 2 | 54 participants (Anticipated) | Interventional | 2022-03-21 | Recruiting | ||
| A Phase II Pilot Trial of Vamorolone vs. Placebo for the Treatment of Becker Muscular Dystrophy[NCT05166109] | Phase 2 | 39 participants (Anticipated) | Interventional | 2022-07-07 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
MRI of leg muscles to measure changes in muscle fat percentage. The data point was collected by taking fat percentage at 6 months minus fat percentage at baseline with the following equation: (([final fat percentage - initial fat percentage]/initial fat percentage) * 100%)). All participants were included, both ambulatory and nonambulatory, with all genetic subtypes included. Five participants didn't have an MRI scan at 6 months and therefore were not included. Muscles imaged were analyzed for muscle fat changes from baseline to 6 months. Data is limited in interpretation due to various muscle groups in both ambulatory and non-ambulatory patients. (NCT04054375)
Timeframe: Baseline, 6 months
| Intervention | percent of change from baseline (Mean) |
|---|---|
| Weekly Steroid | -14 |
time in seconds to walk/run 10 meters , less time to run indicates greater motor function (NCT04054375)
Timeframe: Baseline, Month 6
| Intervention | seconds (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Steroid Treatment | 7.32 | 6.67 |
number of meters walked in 6 minute period. Higher values indicate more motor function. (NCT04054375)
Timeframe: Baseline, Month 6
| Intervention | meters (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Steroid Group | 386 | 410 |
"whole dexa body scan to assess bone density with Z scores (more negative z score indicates increased risk for fractures).~Z-score of 0 represents the population mean, and is the average bone density. Positive scores indicate greater bone density and negative scores indicate decreased bone density, which could be clinically correlated with osteoporosis." (NCT04054375)
Timeframe: Baseline, 6 months
| Intervention | z-score (Mean) | |
|---|---|---|
| baseline | 6 months | |
| Weekly Steroid | -1.64 | -1.65 |
upper extremity assessment, scoring between 1- 6, lower score indicates more upper extremity function (NCT04054375)
Timeframe: Baseline, Month 6
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| baseline | 6 months | |
| Weekly Steroid | 3 | 3 |
units/L, 0-unlimited, higher scores indicate worse outcome (NCT04054375)
Timeframe: Baseline and 6 months (Final Visit)
| Intervention | U/L (Mean) | |
|---|---|---|
| Baseline | End | |
| Weekly Steroid | 1574 | 1047 |
mg/dL, 0-unlimited, higher score indicates worse outcome (NCT04054375)
Timeframe: Baseline and 6 months (Final Visit)
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Baseline | End | |
| Weekly Steroid | 93 | 102 |
cholesterol levels - mg/dL, higher levels indicate worse outcomes (NCT04054375)
Timeframe: Baseline and 6 months (Final Visit)
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Baseline | End | |
| Weekly Steroid | 182 | 185 |
"Northstar Assessment for Dysferlinopathy~- score out of 58, range from 0 to 58, higher score indicates greater functional ability." (NCT04054375)
Timeframe: Baseline, Month 6
| Intervention | score on a scale (Mean) | |
|---|---|---|
| baseline | 6 months | |
| Weekly Steroid | 18.4 | 18.6 |
"Grip strength of the total force (Newtons) in both hands.~Participants attempted 3 trials in the right hand that was then averaged to create a right-hand average force score.~Then, the participants attempted 3 trials in the left hand that was then averaged to create a left-hand average force score.~The right-hand average force score was added to the left-hand average force score to create a total grip strength score." (NCT04054375)
Timeframe: Baseline and 6 months
| Intervention | Force (Newtons) (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Weekly Steroid | 39 | 41 |
% , 0-100, higher score indicates worse outcome (NCT04054375)
Timeframe: Baseline and 6 months (Final Visit)
| Intervention | % A1c (Mean) | |
|---|---|---|
| Baseline | End | |
| Weekly Steroid | 5.2 | 5.3 |
whole body dexa scans to assess lean mass % (0- 100 %). Increase lean mass % is the desired outcome. (NCT04054375)
Timeframe: Baseline, 6 months
| Intervention | percentage (Mean) | |
|---|---|---|
| baseline | 6 months | |
| Weekly Steroid | 37.5 | 38.1 |
Manual motor testing of the right knee flexion muscle group. (NCT04054375)
Timeframe: baseline, 6 months
| Intervention | Units on scale (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Weekly Steroid | 3 | 3 |
Force Vital Capacity (% of predicted value), decrease in FVC indicates declining respiratory function. (NCT04054375)
Timeframe: Baseline, 6 months
| Intervention | % Expected (Mean) | |
|---|---|---|
| Baseline | End | |
| Weekly Steroid | 80 | 79 |
Lower extremity assessment, score from 1-10, lower score indicates more function. (NCT04054375)
Timeframe: Baseline, Month 6
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| baseline | 6 months | |
| Steroid Treatment Group | 5 | 5 |
Vamorolone at 6.0mg/kg/day vs. placebo group in change from baseline to the Week 24 assessment (NCT03439670)
Timeframe: 24 weeks
| Intervention | Rises/Seconds (Mean) |
|---|---|
| Treatment Group 1 | -.007 |
| Treatment Group 2 | 0.054 |
1 trial available for prednisone and Limb-Girdle Muscular Dystrophies
| Article | Year |
|---|---|
An Open Label Exploratory Clinical Trial Evaluating Safety and Tolerability of Once-Weekly Prednisone in Becker and Limb-Girdle Muscular Dystrophy.
Topics: Drug Administration Schedule; Humans; Muscular Dystrophies, Limb-Girdle; Muscular Dystrophy, Duchenn | 2022 |
5 other studies available for prednisone and Limb-Girdle Muscular Dystrophies
| Article | Year |
|---|---|
Intermittent Glucocorticoid Dosing Improves Muscle Repair and Function in Mice with Limb-Girdle Muscular Dystrophy.
Topics: Animals; Dystrophin; Glucocorticoids; Membrane Proteins; Mice; Muscle, Skeletal; Muscular Dystrophie | 2017 |
Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy.
Topics: Animals; Anti-Inflammatory Agents; Cell Differentiation; Cells, Cultured; Dystrophin; Fibrosis; Huma | 2014 |
Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy.
Topics: Animals; Anti-Inflammatory Agents; Cell Differentiation; Cells, Cultured; Dystrophin; Fibrosis; Huma | 2014 |
Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy.
Topics: Animals; Anti-Inflammatory Agents; Cell Differentiation; Cells, Cultured; Dystrophin; Fibrosis; Huma | 2014 |
Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy.
Topics: Animals; Anti-Inflammatory Agents; Cell Differentiation; Cells, Cultured; Dystrophin; Fibrosis; Huma | 2014 |
Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy.
Topics: Animals; Anti-Inflammatory Agents; Cell Differentiation; Cells, Cultured; Dystrophin; Fibrosis; Huma | 2014 |
Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy.
Topics: Animals; Anti-Inflammatory Agents; Cell Differentiation; Cells, Cultured; Dystrophin; Fibrosis; Huma | 2014 |
Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy.
Topics: Animals; Anti-Inflammatory Agents; Cell Differentiation; Cells, Cultured; Dystrophin; Fibrosis; Huma | 2014 |
Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy.
Topics: Animals; Anti-Inflammatory Agents; Cell Differentiation; Cells, Cultured; Dystrophin; Fibrosis; Huma | 2014 |
Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy.
Topics: Animals; Anti-Inflammatory Agents; Cell Differentiation; Cells, Cultured; Dystrophin; Fibrosis; Huma | 2014 |
Glucocorticoid Steroid and Alendronate Treatment Alleviates Dystrophic Phenotype with Enhanced Functional Glycosylation of α-Dystroglycan in Mouse Model of Limb-Girdle Muscular Dystrophy with FKRPP448L Mutation.
Topics: Adrenal Cortex Hormones; Alendronate; Animals; Blotting, Western; Bone Density; Bone Density Conserv | 2016 |
Fukutin gene mutations in steroid-responsive limb girdle muscular dystrophy.
Topics: Anti-Inflammatory Agents; DNA Mutational Analysis; Dystroglycans; Exons; Female; Glycosylation; Huma | 2006 |
The effects of glucocorticoid therapy on the inflammatory and dendritic cells in muscular dystrophies.
Topics: Adolescent; Adult; Analysis of Variance; Biopsy; Child; Child, Preschool; Dendritic Cells; Female; G | 2006 |